ONVOORGANOVO HOLDINGS, INC.

Nasdaq organovo.com


$ 0.54 $ 0.03 (5.69 %)    

Wednesday, 11-Sep-2024 11:27:18 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 0.5496
$ 0.58 x 100
-- x --
-- - --
$ 0.50 - $ 2.05
37,507
na
8.44M
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-31-2024 03-31-2024 10-K
3 02-08-2024 12-31-2023 10-Q
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 07-13-2023 03-31-2023 10-K
7 02-09-2023 12-31-2022 10-Q
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 06-10-2022 03-31-2022 10-K
11 02-14-2022 12-31-2021 10-Q
12 11-08-2021 09-30-2021 10-Q
13 08-06-2021 06-30-2021 10-Q
14 06-15-2021 03-31-2021 10-K
15 02-08-2021 12-31-2020 10-Q
16 11-05-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-28-2020 03-31-2020 10-K
19 02-10-2020 12-31-2019 10-Q
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 06-03-2019 03-31-2019 10-K
23 02-07-2019 12-31-2018 10-Q
24 11-08-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-31-2018 03-31-2018 10-K
27 02-08-2018 12-31-2017 10-Q
28 11-09-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 06-07-2017 03-31-2017 10-K
31 02-09-2017 12-31-2016 10-Q
32 11-03-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 06-09-2016 03-31-2016 10-K
35 02-08-2016 12-31-2015 10-Q
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 06-09-2015 03-31-2015 10-K
39 02-06-2015 12-31-2014 10-Q
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 organovo-granted-us-patent-12037603-methods-for-tissue-fabrication

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037603

 organovo-reports-data-demonstrating-potential-for-fxr314-as-combination-therapy-with-tofacitinib-for-inflammatory-bowel-disease-presented-at-digestive-disease-week

Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches ...

 organovo-granted-us-patent-11982668	use-of-engineered-renal-tissues-in-assays

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11982668

 organovo-holdings-inc-announces-pricing-of-525m-public-offering-of--6562500-shares-of-common-stock--and-common-warrants-at-a-combined-price-of-080

Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company foc...

 why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

 why-organovo-stock-is-up-today
Why Organovo Stock Is Up Today
04/15/2024 14:56:20

Organovo released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-st...

 dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.8...

Core News & Articles
Market-Moving News for April 15th
04/15/2024 12:44:03

GS: 4.5% | Goldman Sachs shares are trading higher after the company reported better-than-expected Q1 EPS and revenues. LGVN: ...

 why-medical-properties-trust-shares-are-trading-higher-by-around-13-here-are-20-stocks-moving-premarket

Shares of Medical Properties Trust, Inc. (NYSE: MPW) rose sharply in today’s pre-market trading after the company announced th...

 organovo-presents-fxr314-3d-human-tissue-model-findings

The presentation highlights preclinical data characterizing the activity of FXR314 in 3D models of human Crohn's disease an...

 organovo-highlights-fxr314-combination-therapy-potential-and-plan

Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in ulcerativ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION